These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 12235266

  • 1. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
    Hough LB, Nalwalk JW, Stadel R, Timmerman H, Leurs R, Paria BC, Wang X, Dey SK.
    J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
    [Abstract] [Full Text] [Related]

  • 2. Significance of cannabinoid CB1 receptors in improgan antinociception.
    Gehani NC, Nalwalk JW, Razdan RK, Martin BR, Sun X, Wentland M, Abood ME, Hough LB.
    J Pain; 2007 Nov; 8(11):850-60. PubMed ID: 17644043
    [Abstract] [Full Text] [Related]

  • 3. Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature.
    Salussolia CL, Nalwalk JW, Hough LB.
    Brain Res; 2007 Jun 04; 1152():42-8. PubMed ID: 17433267
    [Abstract] [Full Text] [Related]

  • 4. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
    Meschler JP, Kraichely DM, Wilken GH, Howlett AC.
    Biochem Pharmacol; 2000 Nov 01; 60(9):1315-23. PubMed ID: 11008125
    [Abstract] [Full Text] [Related]

  • 5. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM, Wakley AA, Tsutsui KT, Laggart JD.
    J Pharmacol Exp Ther; 2012 Mar 01; 340(3):787-800. PubMed ID: 22182934
    [Abstract] [Full Text] [Related]

  • 6. Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms.
    Hough LB, Svokos K, Nalwalk JW.
    Brain Res; 2009 Jan 09; 1247():62-70. PubMed ID: 18983834
    [Abstract] [Full Text] [Related]

  • 7. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
    Sim-Selley LJ, Martin BR.
    J Pharmacol Exp Ther; 2002 Oct 09; 303(1):36-44. PubMed ID: 12235230
    [Abstract] [Full Text] [Related]

  • 8. Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic.
    Hough LB, de Esch IJ, Janssen E, Phillips J, Svokos K, Kern B, Trachler J, Abood ME, Leurs R, Nalwalk JW.
    Neuropharmacology; 2006 Sep 09; 51(3):447-56. PubMed ID: 16806300
    [Abstract] [Full Text] [Related]

  • 9. Cannabinoid-improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor.
    Nalwalk JW, Svokos K, Hough LB.
    Eur J Pharmacol; 2006 Nov 07; 549(1-3):79-83. PubMed ID: 16989809
    [Abstract] [Full Text] [Related]

  • 10. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
    Wagner JA, Járai Z, Bátkai S, Kunos G.
    Eur J Pharmacol; 2001 Jul 06; 423(2-3):203-10. PubMed ID: 11448486
    [Abstract] [Full Text] [Related]

  • 11. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor.
    Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, Blau H, Mechoulam R.
    Eur J Pharmacol; 2003 Feb 07; 461(1):27-34. PubMed ID: 12568912
    [Abstract] [Full Text] [Related]

  • 12. CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia.
    Rawls SM, Cabassa J, Geller EB, Adler MW.
    J Pharmacol Exp Ther; 2002 Jun 07; 301(3):963-8. PubMed ID: 12023525
    [Abstract] [Full Text] [Related]

  • 13. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands.
    Smith SR, Terminelli C, Denhardt G.
    Eur J Pharmacol; 2001 Aug 03; 425(1):73-83. PubMed ID: 11672577
    [Abstract] [Full Text] [Related]

  • 14. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
    Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F.
    Eur J Pharmacol; 1999 Nov 12; 384(1):37-42. PubMed ID: 10611417
    [Abstract] [Full Text] [Related]

  • 15. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
    Darmani NA, Sim-Selley LJ, Martin BR, Janoyan JJ, Crim JL, Parekh B, Breivogel CS.
    Eur J Pharmacol; 2003 Jan 10; 459(1):83-95. PubMed ID: 12505537
    [Abstract] [Full Text] [Related]

  • 16. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.
    Wiley JL, Lowe JA, Balster RL, Martin BR.
    J Pharmacol Exp Ther; 1995 Oct 10; 275(1):1-6. PubMed ID: 7562536
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory effects of SR141716A on G-protein activation in rat brain.
    Sim-Selley LJ, Brunk LK, Selley DE.
    Eur J Pharmacol; 2001 Mar 02; 414(2-3):135-43. PubMed ID: 11239913
    [Abstract] [Full Text] [Related]

  • 18. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A.
    Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH.
    J Pharmacol Exp Ther; 1998 Aug 02; 286(2):697-703. PubMed ID: 9694923
    [Abstract] [Full Text] [Related]

  • 19. CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist.
    Hough LB, Nalwalk JW, Phillips JG, Kern B, Shan Z, Wentland MP, de Esch IJ, Janssen E, Barr T, Stadel R.
    Neuropharmacology; 2007 Apr 02; 52(5):1244-55. PubMed ID: 17336343
    [Abstract] [Full Text] [Related]

  • 20. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.
    Gómez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodríguez de Fonseca F.
    J Neurosci; 2002 Nov 01; 22(21):9612-7. PubMed ID: 12417686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.